LDN 57444
(Synonyms: Ubiquitin C-terminal Hydrolase L1 Inhibitor, UCHL1 Inhibitor) 目录号 : GC10510
一键复制产品信息
LDN 57444是一种小分子抑制剂，可阻断UCHL1的去泛素化酶活性（Ki=0.40μM；IC50=0.88μM），抑制UCHL3的IC50值为25μM。
Cas No.:668467-91-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
LDN 57444 is a small molecular inhibitor that can block UCHL1 deubiquitinase activity (Ki=0.40μM; IC50=0.88μM), with an IC50 value of 25μM for inhibiting UCHL3 [1]. LDN 57444 suppresses mouse oocyte maturation by improving oxidative stress, attenuating mitochondrial function, curbing spindle body formation and down-regulating extracellular signal-related kinases (ERK1/2) expression [2]. LDN 57444 has been widely used to inhibit the invasive ability of nasopharyngeal cancer cells and reduce the adhesion of cancer cells[3].
In vitro, LDN 57444 treatment (50μM) for 24 hours significantly triggered apoptosis in SK-N-SH cells and inhibited the ubiquitin-proteasome system and induced endoplasmic reticulum stress[4]. Treatment with 10μM LDN 57444 for 24 hours significantly inhibited the migration of human dermal fibroblasts (HDFs) and upregulated the phosphorylation of Smad2 and Smad3[5].
In vivo, LDN 57444 treatment via daily intraperitoneal injection at a dose of 40μg/kg for 3 weeks significantly reduced atrial fibrillation induced by angiotensin II in mice[6]. Daily intraperitoneal injection of 5mg/kg dose of LDN 57444 for 14 days can result in a reduced number of metastatic foci in the lungs and liver of mice with DU-145 xenograft tumors[7]. Daily intraperitoneal injection of 20μg/kg dose of LDN 57444 for 4 months can lower the blood pressure of spontaneously hypertensive rats and improve the cardiac function[8].
References:
[1] Liu Y, Lashuel H A, Choi S, et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line[J]. Chemistry & biology, 2003, 10(9): 837-846.
[2] Yuan P, Zhou L, Zhang X, et al. UCH-L1 inhibitor LDN-57444 hampers mouse oocyte maturation by regulating oxidative stress and mitochondrial function and reducing ERK1/2 expression[J]. Bioscience Reports, 2020, 40(10): BSR20201308.
[3] Kobayashi E, Hwang D, Bheda-Malge A, et al. Inhibition of UCH-L1 deubiquitinating activity with two forms of LDN-57444 has anti-invasive effects in metastatic carcinoma cells[J]. International journal of molecular sciences, 2019, 20(15): 3733.
[4] Tan Y Y, Zhou H Y, Wang Z Q, et al. Endoplasmic reticulum stress contributes to the cell death induced by UCH-L1 inhibitor[J]. Molecular and cellular biochemistry, 2008, 318(1): 109-115.
[5] Pan H, Song J, An Q, et al. Inhibition of Ubiquitin C‐Terminal Hydrolase L1 Facilitates Cutaneous Wound Healing via Activating TGF‐β/Smad Signalling Pathway in Fibroblasts[J]. Experimental Dermatology, 2024, 33(10): e15186.
[6] Bi H L, Zhang Y L, Yang J, et al. Inhibition of UCHL1 by LDN-57444 attenuates Ang II–Induced atrial fibrillation in mice[J]. Hypertension Research, 2020, 43(3): 168-177.
[7] Liu S, Garcia-Marques F J, Shen M, et al. Ubiquitin C-terminal hydrolase L1 is a regulator of tumor growth and metastasis in double-negative prostate cancer[J]. American Journal of Clinical and Experimental Urology, 2024, 12(5): 306.
[8] Han X, Zhang Y L, Fu T, et al. Blockage of UCHL1 activity attenuates cardiac remodeling in spontaneously hypertensive rats[J]. Hypertension Research, 2020, 43(10): 1089-1098.
LDN 57444是一种小分子抑制剂，可阻断UCHL1的去泛素化酶活性（Ki=0.40μM；IC50=0.88μM），抑制UCHL3的IC50值为25μM[1]。LDN 57444通过加剧氧化应激、减弱线粒体功能、抑制纺锤体形成和下调细胞外信号调节激酶(ERK1/2)的表达，从而抑制小鼠卵母细胞的成熟[2]。LDN 57444已被广泛用于抑制鼻咽癌细胞的侵袭能力并降低癌细胞的粘附[3]。
在体外，50μM的LDN 57444处理SK-N-SH细胞24小时，显著触发了细胞凋亡，抑制了泛素-蛋白酶体系统并诱导了内质网应激[4]。10μM的LDN 57444处理人真皮成纤维细胞(HDFs) 24小时，显著抑制了细胞迁移，并上调了Smad2和Smad3的磷酸化[5]。
在体内，每日腹腔注射40μg/kg剂量的LDN 57444，持续3周，显著减少了血管紧张素II诱导的小鼠心房颤动[6]。每日腹腔注射5mg/kg剂量的LDN 57444，持续14天，可导致DU-145异种移植瘤小鼠肺和肝中的转移灶数量减少[7]。每日腹腔注射20μg/kg剂量的LDN 57444，持续4个月，可降低自发性高血压大鼠的血压并改善心脏功能[8]。
| Cell experiment [1]: | |
Cell lines | SK-N-SH cells |
Preparation Method | SK-N-SH cells were incubated with DMEM-H medium supplemented with 10% fetal calf serum (FCS), and 1% penicillin/streptomycin in a humidified atmosphere at 37°C with 5% CO2. Cells were cultured in a 96-well culture plate at 5×104 cells/well. After 24h cultured at 37°C in the atmosphere of 5% CO2, cells were treated with different concentrations of LDN 57444 (0, 5, 10, 25, 50, 75, and 100μM) and incubated for 24h. Cell viability was measured. |
Reaction Conditions | 0, 5, 10, 25, 50, 75, and 100μM; 24h |
Applications | LDN 57444 treatment significantly reduced the cell viability of SK-N-SH cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Spontaneously hypertensive rats |
Preparation Method | Spontaneously hypertensive rats (2-month-old; 240-280g) were kept in an air-conditioned room at 24-25°C with a 12-h light/dark cycle. LDN 57444 was administered intraperitoneally in rats from 2 months of age for 4 months at the dose of 20μg/kg/day. Blood pressure was measured in all rats every month, and the hearts of rats were collected for analysis. |
Dosage form | 20μg/kg/day for 4 months; i.p. |
Applications | LDN 57444 treatment reduced blood pressure and attenuated cardiac hypertrophy and fibrosis in rats. |
References: | |
| Cas No. | 668467-91-2 | SDF | |
| 别名 | Ubiquitin C-terminal Hydrolase L1 Inhibitor, UCHL1 Inhibitor | ||
| 化学名 | [(Z)-[5-chloro-1-[(2,5-dichlorophenyl)methyl]-2-oxoindol-3-ylidene]amino] acetate | ||
| Canonical SMILES | CC(=O)ON=C1C2=C(C=CC(=C2)Cl)N(C1=O)CC3=C(C=CC(=C3)Cl)Cl | ||
| 分子式 | C17H11Cl3N2O3 | 分子量 | 397.64 |
| 溶解度 | ≥ 16.7 mg/mL in DMSO with gentle warming | 储存条件 | Desiccate at 4°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5148 mL | 12.5742 mL | 25.1484 mL |
| 5 mM | 503 μL | 2.5148 mL | 5.0297 mL |
| 10 mM | 251.5 μL | 1.2574 mL | 2.5148 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet